Status:
COMPLETED
Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Lead Sponsor:
Altair Therapeutics, Inc.
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
To assess the efficacy of inhaled AIR645 in the suppression of the Asthmatic Responses in subjects with mild asthma inhaling an allergen.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Men and women with well controlled mild allergic asthma, aged 18 to 65 years
- Only asthma med is short-acting bronchodilator used not more than twice weekly
- FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction
Exclusion
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00941577
Start Date
October 1 2009
End Date
June 1 2010
Last Update
July 23 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamilton, Ontario, Canada
2
Laval, Quebec, Canada
3
Saskatoon, Saskatchewan, Canada